CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Most Recent Articles

Providence Saint Joseph Medical Center is now offering treatment with Inspire implant , a leading-edge treatment designed to help patients breathe naturally during sleep.

Caregivers gathered in March to train for complex emergency scenarios involving hazardous materials.

Joe's journey with our LVAD program shows what’s possible when exceptional care gives patients more time to thrive.

This study is now enrolling patients at Providence Cancer Institute – the only site outside of Australia.

Colon cancer is one of the most preventable cancers when caught early, yet it remains a leading cause of cancer related deaths in the United States.

Providence Alaska Medical Center (PAMC) received a $430,000 national grant recognizing its critical role in preparing for and responding to infectious diseases.

Dr. Kelly Perlewitz answers timely questions about the rise of colon cancer cases in younger adults.

A nurse-designed space expands access to care and helps patients move smoothly through their hospital stay.

We celebrate the work of oncology social workers, whose work is essential, transformative and deeply human.

Providence today announced it is actively exploring strategic options for Providence Health Plan (PHP) – including the sale of the plan.

On Feb. 28, 2026, Providence South Division Philanthropy hosted the annual Physician Champion Awards at The Langham Huntington in Pasadena.

Our center for weight management recently hosted a free seminar focused on helping participants better understand evidence-based weight management approaches.

Palliative care can help manage pain, fatigue, anxiety and so much more – at any stage of cancer treatment.

Providence has released a toolkit to guide other organizations in using technology to support environmental stewardship efforts.

Providence Medford partnered with St. Mary’s School to hold a two-week internship designed to give local high school students a look at several health care professions.

See photos of one of three new electrophysiology labs and learn about improved features for patients and caregivers.

Providence Holy Cross Medical Center was honored with the 2026 Patient Safety Excellence Award™ from Healthgrades, the nation’s leading consumer health resource.

AI Mammogram Technology Offers 23% Greater Cancer Detection, Fewer False Positives